Actively Recruiting
SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization
Led by CrannMed · Updated on 2025-11-21
45
Participants Needed
1
Research Sites
71 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from pain secondary to plantar fasciitis.
CONDITIONS
Official Title
SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent
- Aged 18 to 75 years (inclusive)
- Clinical diagnosis of plantar fasciitis with proximal plantar fascia thickness greater than 4mm and areas of hypoechogenicity
You will not qualify if you...
- Acute internal derangement of the foot including acute meniscal, ligament, or bone injury
- Sensory or motor neuropathy of the feet
- Heel pain caused by stress fractures, nerve entrapment, or inflammatory conditions such as arthritis, gout, or bursitis
- Prior surgical repair or plantar fascia rupture in the involved foot
- Local infection in either foot
- Contraindication to MRI
- Active pregnancy or lactating female
- Unable to provide informed consent or comply with study conditions
- At the discretion of the Principal Investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nano Medical Clinic
Tashkent, Uzbekistan, Uzbekistan, 100095
Actively Recruiting
Research Team
C
Chief Operations Officer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here